新一代细菌性阴道炎治疗药物塞克硝唑的药理与临床  

Pharmacological effects and clinical evaluation of secnidazole:a next-generation antimicrobial agent for bacterial vaginosis treatment

作　　者：罗太敏 姜晨晨 吴娜[1] 杜燕京[1] 封宇飞[1] LUO Tai-min;JIANG Chen-chen;WU Na;DU Yan-jing;FENG Yu-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China)

机构地区：[1]北京医院药学部国家老年医学中心药物临床风险与个体化应用评价北京市重点实验室,北京100730

出　　处：《临床药物治疗杂志》2018年第10期5-7,31,共4页Clinical Medication Journal

摘　　要：塞克硝唑是新一代硝基咪唑类药物,已经在欧洲、亚洲、南美洲和非洲等31个国家上市30多年。2017年9月15日,美国食品药品监督管理局(FDA)批准本品颗粒制剂上市,用于治疗成年女性的细菌性阴道炎。现对其作用机制、药动学、临床评价及安全性等进行综述。Secnidazole, a next-generation 5-nitroimidazole, has been commercially available for more than three decades, with current approvals in 31 countries within Europe, Asia, South America and Africa. The US FDA recently approved a novel granule formulation of secnidazole for the treatment of adult female bacterial vaginitis. The mechanism, pharmacological actions, related clinical researches about the efficacy and safety of secnidazole were reviewed in this paper.

关 键 词：塞克硝唑 细菌性阴道炎 5-硝基咪唑类药物 药理作用 临床评价 

分 类 号：R978.5[医药卫生—药品]